PARIS (Agefi-Dow Jones)–The pharmaceutical company Sanofi announced on Sunday positive results for its drug Sarclisa, in combination with carfilzomib and dexamethasone, in the treatment of patients with relapsed multiple myeloma treated with an inhibitor. of the proteasome.
“The latest results from the IKEMA Phase III clinical trial evaluating Sarclisa in combination with carfilzomib and dexamethasone show that this therapeutic combination achieved a median progression-free survival of 35.7 months, as assessed by an independent committee,” Sanofi said in a statement.
“These results attest to the longest median progression-free survival ever observed in studies devoted to a second-line disease-modifying treatment of relapsed multiple myeloma with a proteasome inhibitor”, added the laboratory.
Multiple myeloma is the second most common blood cancer, with more than 130,000 new cases diagnosed each year worldwide.
Sarclisa has already been approved in a number of countries, including the United States and European Union countries, in combination with pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma in adults who have received at least two previous treatments.
-Dimitri Delmond, Agefi-Dow Jones; +33 (0)1 41 27 47 31; [email protected] ed: VLV
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
May 16, 2022 01:12 ET (05:12 GMT)